GENEVA, July 18 -- IMMATICS BIOTECHNOLOGIES GMBH filed a patent application (EP2026/050707) for “BISPECIFIC TCER AGAINST A MAGEA4- AND A PRAME-DERIVED PEPTIDE IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR FOR USE IN TREATING CANCER”. With publication no. WO/2026/150149, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: C07K 14/725
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....